Wearable Injectors Market is Segmented By Type (Off-Body Injectors, Infusion Sets, Others ), By Therapy( Autoimmune Disease, Diabetes, Cardiovascular Disease, Other), By End-User (Hospitals and Clinics, Homecare, Others), By End-User (Automotive, Aerospace, Safety, Medical, Energy, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030.
[150 Pages Report] Wearable Injectors Market is expected to reach at a CAGR of 11.7% during the forecast period (2023-2030). Wearable injectors are delivery systems that adhere to the body and allow for administering larger volumes of the drug (more than 2 mL) subcutaneously over an extended period.
Wearable Injectors Market Summary and Scope
|
Metrics |
Details |
|
Market CAGR |
11.7% |
|
Segments Covered |
By Type, By Therapy, By End-User, By Application, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
To Get a Free Sample Click here
Wearable Injectors Market Dynamics and Trends
The factors affecting the global wearable injectors market are the technological advancements, and the growing prevalence of diseases is expected to drive the market growth.
The technological advancements are expected to drive the market growth in the forecast period
Wearable injectors, which automatically inject the patient with the exact dose of medicine at predetermined intervals, help reduce the burden on doctors and other healthcare workers. These devices will continue to be used as a temporary care solution, reducing the need for regular visits to healthcare facilities to receive specific medications. In recent years, the development of concentrated monoclonal antibodies has proven effective in treating various chronic illnesses. However, for these treatments to be effective, precise doses must be administered by a healthcare professional, often intravenously. Wearable injector innovations are now allowing thousands of patients to receive injections from the comfort of their own homes. The volume and viscosity of doses used in wearable injectors are addressed in modern devices. Wearable injectors are used for high-volume medications, pharmaceutical formulations with high viscosities (e.g., monoclonal antibodies), and long-term regimens requiring timed medication injection. When wearable injectors are used as an alternative to admitting the patient to a medical facility for clinical support of an injection, on-body injectors are most useful. Wearable injectors offer patients a home-based alternative to unnecessary and potentially dangerous trips to the clinic or hospital for injection support while ensuring timely and effective preventive care for chronic conditions.
Hence, wearable injectors' increasing technological advancements and advantages are expected to drive market growth.
The problems associated with wearable injectors is expected to hamper the market growth
The disadvantages of wearable injectors manufacturing include physical barriers when attempting to move around the equipment. Physical impediments when attempting to reposition the equipment, Conveyors of sufficient length provide sufficient buffering, Pucks, nests, and other similar items transport in the middle platform required for upkeep for position or orientation, the following machine. Increased capital investment, docking station design and logistics required, trays or other intermediate transport platforms required to facilitate transfer to next machine. The problems associated with the manufacturing of wearable injectors are also expected to hamper the market growth.
COVID-19 Impact Analysis on Wearable Injectors Market
Currently, an increase in chronic ailments caused by COVID morbidity will fuel growth in the adoption of OBI (On-body wearable injectors) solutions as patients with chronic pulmonary, cardiovascular, and neurological conditions begin to manage the disease's long-term effects. Globally, approximately 146 million patients have recovered from COVID, with approximately one-third of these survivors requiring support for the treatment of "long-term" conditions. Patients with chronic diseases are demanding a shift from clinic to at-home drug delivery to protect themselves from COVID exposure in the clinic and recognize that conditions such as immune deficiency disorders result in vaccine resistance and predispose patients to prolonged illness due to COVID. Hence, the wearable injectors market is expected to grow due to the COVID-19 impact.
Wearable Injectors Market Segment Analysis
On-body injectors segment is expected to dominate the global wearable injectors market
On-body injectors, also known as on-body delivery systems (OBDS), typically deliver a pre-measured amount of medicine to the patient, often automatically via a needle, ensuring that the patient does not miss a treatment or incorrectly adhere to their own medicine. It enables a stable recovery platform because the patient is not moved or transferred to receive critical medicine. Patients can also receive the correct dose in the correct location for optimal treatment profiles. With pharmaceutical companies preferring to use larger molecules with higher delivery volumes, OBDSs offers a unique opportunity to easily deliver potent medicine to patients. Still, caution must be exercised due to the increased risk if something goes wrong in this process. OBIs are device platforms with optional connectivity expected to close critical gaps in healthcare infrastructure and connected health services. OBIs are expected to grow at a compound annual growth rate of 16% through 2025, with growth potentially exceeding these figures as OBI is used to treat both acute COVID and the aftereffects of an illness.
Furthermore, on February 4, 2021, Phillips-Medisize and MedTech devices collaborated with Subcuject, a global innovator of proprietary device platforms, to market wearable bolus injectors. The On-Body Delivery System technology based on osmosis is now available for the next stage of drug-specific wearable injector solution development.
Wearable Injectors Market Geographical Share
North America region is expected to hold the largest market share in the global wearable injectors market
The increasing prevalence of diseases in this region is expected to drive market growth. For instance, in 2018, 1,708,921 new cancer cases were reported in the United States, and 599,265 people died from cancer. 436 new cancer cases were reported for every 100,000 people, and 149 people died due to cancer in 2018. This figure indicates that the prevalence of cancer in the United States is rapidly increasing. Breast cancer, lung cancer, prostate cancer, colon and rectal cancer, bladder cancer, and skin cancer are the most common cancers in the U.S.
Diabetes also has a more significant health impact on Americans than heart disease, substance use disorder, or COPD, according to the American Diabetes Association, with 30.3 million Americans diagnosed with the illness and many more at risk of developing it. The prevalence of these diseases is expected to drive up demand for wearable injectors throughout the region. Moreover, the presence of major market players in the United States, such as Becton, Dickinson and Company, Johnson & Johnson Services, Inc., Unilife Corporation, SteadyMed Therapeutics, Inc., Amgen, Inc., and Enable Injections, is expected to drive market growth.
Wearable Injectors Companies and Competitive Landscape
Wearable injectors market is moderately competitive. Some of the key players in the market are Becton, Dickinson and Company, Ypsomed AG., Amgen, Inc., Insulet Corporation, Enable Injections, West Pharmaceutical Services, Inc., CeQur SA, Sonceboz, Tandem Diabetes Care, Inc., Medtronic PLC
Becton, Dickinson, and Company
Overview: Becton, Dickinson, and Company, or BD, is a multinational medical technology company based in the United States that manufactures and sells medical devices, instrument systems, and reagents. In certain geographies, BD also offers consulting and analytics services. The company was founded in 1897.
Product Portfolio: The company's BD libertas wearable injector is intended to be a pre-filled drug delivery system for combination products. The BD Libertas Wearable Injector is a cutting-edge injection system that can deliver complex biologics with viscosities up to 50 cP in 2-5 mL and 5-10 mL configurations at home or in clinical settings.
Key Development: On 12th February 2020, the company completed a 50-person human clinical trial with the BD Libertas Wearable Injector. The purpose of the study was to assess the performance of the 5 mL BD Libertas device in human subjects, including tissue effects, skin reactivity, and patient acceptance.